Willy Küng

584 total citations
15 papers, 479 citations indexed

About

Willy Küng is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Willy Küng has authored 15 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Genetics and 8 papers in Oncology. Recurrent topics in Willy Küng's work include Estrogen and related hormone effects (9 papers), HER2/EGFR in Cancer Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Willy Küng is often cited by papers focused on Estrogen and related hormone effects (9 papers), HER2/EGFR in Cancer Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Willy Küng collaborates with scholars based in Switzerland, France and United States. Willy Küng's co-authors include Urs Eppenberger, Katja Wosikowski, Doriano Fabbro, Romano Regazzi, Reto Ritschard, Christoph Rochlitz, Christoph Mamot, Richard Herrmann, Jonas Cicenas and Serenella Eppenberger‐Castori and has published in prestigious journals such as Biochemical and Biophysical Research Communications, European Journal of Biochemistry and International Journal of Cancer.

In The Last Decade

Willy Küng

15 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Willy Küng Switzerland 11 286 181 124 73 62 15 479
Toshiaki Segawa Japan 9 359 1.3× 81 0.4× 42 0.3× 103 1.4× 63 1.0× 9 621
R. Cowen United Kingdom 8 222 0.8× 111 0.6× 64 0.5× 28 0.4× 19 0.3× 12 480
Jesika S. Faridi United States 11 329 1.2× 108 0.6× 53 0.4× 17 0.2× 29 0.5× 19 536
Eva María Ciruelos Gil Spain 3 253 0.9× 331 1.8× 80 0.6× 46 0.6× 19 0.3× 6 568
Silke Erdmann Germany 14 384 1.3× 112 0.6× 50 0.4× 6 0.1× 53 0.9× 15 609
Giovanni Brigliadori Italy 13 256 0.9× 199 1.1× 27 0.2× 37 0.5× 32 0.5× 21 486
Soleilmane Omarjee United Kingdom 10 273 1.0× 176 1.0× 63 0.5× 114 1.6× 10 0.2× 13 440
María A. Jasnis Argentina 15 238 0.8× 184 1.0× 24 0.2× 60 0.8× 12 0.2× 26 519
Sara L. O’Kane United Kingdom 10 237 0.8× 119 0.7× 19 0.2× 49 0.7× 32 0.5× 17 436
LaTonia Taliaferro‐Smith United States 8 362 1.3× 240 1.3× 35 0.3× 33 0.5× 9 0.1× 13 556

Countries citing papers authored by Willy Küng

Since Specialization
Citations

This map shows the geographic impact of Willy Küng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willy Küng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willy Küng more than expected).

Fields of papers citing papers by Willy Küng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willy Küng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willy Küng. The network helps show where Willy Küng may publish in the future.

Co-authorship network of co-authors of Willy Küng

This figure shows the co-authorship network connecting the top 25 collaborators of Willy Küng. A scholar is included among the top collaborators of Willy Küng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willy Küng. Willy Küng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Mamot, Christoph, Reto Ritschard, Andreas Wicki, et al.. (2012). Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting. 20(5). 422–432. 42 indexed citations
2.
Cicenas, Jonas, Willy Küng, Urs Eppenberger, & Serenella Eppenberger‐Castori. (2010). Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor. Cancers. 2(1). 153–164. 5 indexed citations
3.
Cicenas, Jonas, Patrick Urban, Willy Küng, et al.. (2006). Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. European Journal of Cancer. 42(5). 636–645. 56 indexed citations
4.
Breuleux, Madlaina, et al.. (2006). Heregulins Implicated in Cellular Functions Other Than Receptor Activation. Molecular Cancer Research. 4(1). 27–37. 16 indexed citations
5.
Mamot, Christoph, Reto Ritschard, Willy Küng, et al.. (2006). EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. Journal of drug targeting. 14(4). 215–223. 51 indexed citations
6.
Cicenas, Jonas, Patrick Urban, Vincent Vuaroqueaux, et al.. (2005). Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Research. 7(4). R394–401. 51 indexed citations
7.
Wosikowski, Katja, Willy Küng, Max Hasmann, R. Löser, & Urs Eppenberger. (1993). Inhibition of growth‐factor‐activated proliferation by anti‐estrogens and effects on early gene expression of mcf‐7 cells. International Journal of Cancer. 53(2). 290–297. 40 indexed citations
8.
Wosikowski, Katja, Urs Eppenberger, Willy Küng, Yoshikuni Nagamine, & Heinz Mueller. (1992). C-fos, C-jun and C-myc expressions are not growth rate limiting for the human MCF-7 breast cancer cells. Biochemical and Biophysical Research Communications. 188(3). 1067–1076. 14 indexed citations
9.
Eppenberger, Urs, Katja Wosikowski, & Willy Küng. (1991). Pharmacologic and Biologic Properties of Droloxifene, A New Antiestrogen. American Journal of Clinical Oncology. 14. 5–14. 65 indexed citations
10.
Fabbro, Doriano, Willy Küng, Serban Dan Costa, et al.. (1991). Involvement of protein kinase C in the growth regulation of human breast cancer cells. Cancer treatment and research. 61. 229–248. 9 indexed citations
11.
Scott‐Burden, Timothy, et al.. (1990). Modulation of extracellular‐matrix synthesized by cultured stromal cells from normal human breast tissue by epidermal growth factor. Journal of Cellular Biochemistry. 43(2). 111–125. 4 indexed citations
12.
Novak‐Hofer, Ilse, Willy Küng, Doriano Fabbro, & Urs Eppenberger. (1987). Estrogen stimulates growth of mammary tumor cells ZR‐75 without activation of S6 kinase and S6 phosphorylation. European Journal of Biochemistry. 164(2). 445–451. 10 indexed citations
13.
Fabbro, Doriano, Willy Küng, Werner Roos, Romano Regazzi, & Urs Eppenberger. (1986). Epidermal growth factor binding and protein kinase C activities in human breast cancer cell lines: possible quantitative relationship.. PubMed. 46(6). 2720–5. 64 indexed citations
14.
Costa, Serban Dan, Doriano Fabbro, Romano Regazzi, Willy Küng, & Urs Eppenberger. (1985). The cytosolic phorboid receptor correlates with hormone dependency in six mammary carcinoma cell lines. Biochemical and Biophysical Research Communications. 133(2). 814–822. 19 indexed citations
15.
Küng, Willy, et al.. (1980). Quantitative estimation of cellular retinoic acid-binding protein activity in normal, dysplastic, and neoplastic human breast tissue.. PubMed. 40(11). 4265–9. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiaki Segawa Breakdown of academic impact, for papers by R. Cowen Breakdown of academic impact, for papers by Jesika S. Faridi Breakdown of academic impact, for papers by Eva María Ciruelos Gil Breakdown of academic impact, for papers by Silke Erdmann Breakdown of academic impact, for papers by Giovanni Brigliadori Breakdown of academic impact, for papers by Soleilmane Omarjee Breakdown of academic impact, for papers by María A. Jasnis Breakdown of academic impact, for papers by Sara L. O’Kane Breakdown of academic impact, for papers by LaTonia Taliaferro‐Smith
Rankless by CCL
2026